August 4, 2026 Deadline: Join Class Action Lawsuit Against GRAIL, Inc. (GRAL) - Contact Levi & Korsinsky
NEW YORK CITY, NY / ACCESS Newswire / June 11, 2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired GRAIL, Inc. (NASDAQ:GRAL) securities.
If you suffered a loss on your GRAIL investment and would like to explore a potential recovery under the federal securities laws, Learn about GRAIL Class Action or contact Joseph E. Levi, Esq. via email at [email protected] or call (212)363-7500 to speak to our team of experienced shareholder advocates.
THE LAWSUIT: A class action securities lawsuit was filed against GRAIL, Inc. that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between May 13, 2025 and February 19, 2026.
CASE DETAILS: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of GRAIL's NHS-Galleri trial following the reveal of the top-line results covering the first screening round. Notably, as defendants have since attested, the trial as executed within the three-year follow-up period was insufficient to demonstrate the achievability of a reduction in Stage III-IV cancers; defendants disclosed the trial period, and thus the screening duration, was apparently insufficient to demonstrate whether the primary endpoint was achievable. Defendants further repeatedly refused to provide detailed topline results or other data from the NHS-Galleri study, potentially concealing known trendlines which arguably suggested either a longer timeline would be necessary or otherwise that the probability of achieving the statistical reduction in Stage III & IV cancers by the trial's end had been reduced.
On February 19, 2026, GRAIL announced that the "primary endpoint of statistically significant Stage III-IV reduction was not observed" in the NHS-Galleri Trial. The Company attributed this shortcoming, in part, on "probably need[ing] a longer follow-up time to be able to [compare the study arms] adequately."
Following this news, the price of GRAIL's common stock declined dramatically. From a closing market price of $101.53 per share on February 19, 2026, Grail's stock price fell to $50.21 per share on February 20, 2026, a decline of about 50.55% in the span of just a single day.
WHAT'S NEXT? If you purchased GRAIL stock during the relevant time frame - even if you still hold your shares, learn about your rights to seek a recovery. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212)363-7500
Fax: (212) 363-7171
SOURCE: Levi & Korsinsky, LLP